Epilepsy Drugs Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics,  and Third Generation Anti-Epileptics), Distribut

Epilepsy Drugs Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics,  and Third Generation Anti-Epileptics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy Stores, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

The epilepsy drugs market size was valued at US$ 7.768 billion in 2022 and is projected to reach US$ 10.705 billion by 2030; it is estimated to register a CAGR of 4.1% from 2022 to 2030. The epilepsy drugs market growth is primarily driven by the increasing prevalence of epilepsy and an increasing number of elderly people.

Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management.

Several Epilepsy Drugs Nearing Patent Expiration Creating Opportunities for Epilepsy Drugs Market Growth

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Company Patent Patent Expiration Date Ingredient Treatment

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy
GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy
Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures
SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies
SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

Treatment-Based Insights

The epilepsy drugs market, by treatment, is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share; the third generation anti-epileptics is estimated to register the fastest CAGR during 2022–2030. The second-generation AEDs include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and zonisamide. In North America and Europe, ZNS is also considered a second-generation drug. The higher cost of second-generation AEDs compared with first-generation drugs is a significant factor limiting their mention in formularies. The second-generation AEDs have a more favorable side-effect profile and a lower risk of teratogenesis compared with first-generation drugs. Many first-generation and several second-generation (AEDs) share a common feature of enzyme induction that can increase the metabolism of different substrates targeted by the cytochrome p450 enzyme, along with a decrease in the action of the inducer.

Distribution Channel-Based Insights

The epilepsy drugs market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacies segment held the largest market share; the retail pharmacy segment is anticipated to register the fastest CAGR during 2022–2030. Hospital pharmacies purchase pharmaceuticals from different companies and supply them to hospitals for outpatient or inpatient treatments. Hospital pharmacies usually offer therapeutic and critical care drugs that have applications in cardiology, neurology, urology, pathology, hematology, and dermatology. Hospital pharmacies are among the essential parts of the healthcare system of any country. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, hospital pharmacies hold a considerable size of the epilepsy drug market.

A few of the major primary and secondary sources referred to while preparing the report on the epilepsy drugs market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Investor presentations and Annual Reports of Market players.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the epilepsy drugs market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global epilepsy drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the epilepsy drugs market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.